Navigation Links
Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
Date:2/4/2013

nt selection marker for response to ARRY-520.  A related presentation assessing the same group of ARRY-520-treated patients observed that, for patients retrospectively selected with a lower AAG level, the overall response rate (≥PR) increased to 33% (from 22%) with a median time on study of 6.2 months.  The clinical benefit rate (≥MR) was 50% in the selected population. 

Interim data from an ongoing investigator-sponsored combination trial of ARRY-520 with Kyprolis in patients with relapsed or refractory MM who are refractory or intolerant to Velcade® (bortezomib) were also reported at the conference.  The combination has demonstrated early signals of activity, with a 56% clinical benefit rate (≥MR). In addition, it has been well tolerated with limited hematologic toxicity and a manageable side effect profile.

ARRY-614 – FDA meeting provides guidance on primary endpointDuring the quarter, Array continued to evaluate ARRY-614 in an ongoing clinical trial in patients with low or intermediate-1 risk MDS using an optimized formulation. As presented at ASH, this new formulation has demonstrated improved bioavailability and target coverage in this patient population. With this new formulation, peak plasma concentrations and overall exposures are higher than with the original formulation. The ongoing Phase 1 dose escalation trial of the optimized ARRY-614 formulation may further our understanding of the contributions of these targets to the pathogenesis of MDS.  In a prior study in a similar population, up to a 40% response rate for hematologic improvement was observed in patients. 

Array also met with the FDA to discuss the development plan to support registration and received guidance from the FDA on the primary endpoint, including a discussion of endpoints other than overall survival that could be used as the basis for approval.  Array has now defined a potential p
'/>"/>

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems based on Single Molecule Array Technology
2. Maine Manufacturing, LLC Announces Global Distribution of FAST® Protein Array Products
3. Self-assembling nanorods: Berkeley Lab researchers obtain 1-, 2- and 3-D nanorod arrays and networks
4. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
5. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
6. Solar nanowire array may increase percentage of suns frequencies available for energy conversion
7. Array BioPharma to Hold Conference Call on Monday, November 5, 2012 to Discuss Submitted ASH Abstracts
8. Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
9. John A. Orwin Joins Array BioPharma Board Of Directors
10. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
11. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... 27, 2015  Ceres, Inc. (Nasdaq: CERE ), ... patent for a genetic sequence derived from soybean, covering ... product development and plant transformation. The company believes that ... that are the target of a class of commercial ... commercial license to the innovation, including an opportunity for ...
(Date:5/27/2015)... MARLBOROUGH, Mass. , May 27, 2015 /PRNewswire/ ... biotechnology company focused on discovering and developing innovative ... ophthalmology, today provided an update on the status of ... Stock. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... there were 3,085 and 21 shares of Series ...
(Date:5/27/2015)... ­ Caris Life Sciences®, a leading biotechnology ... today announced it has appointed the Levine Cancer Institute, ... site in the Caris Centers of Excellence for Precision ... is one of the largest cancer care providers throughout ... patients annually. Derek Raghavan , M.D., Ph.D., President ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4
... HARBIN, China , May ... ("China Sky One Medical" or "the Company") (Nasdaq: ... producing over-the-counter drugs in, the People,s Republic of ... Long,Pharmaceutical Company ("Tian Long") subsidiary successfully obtained renewal,of ...
... NEW YORK , May 27 Pfizer Inc. (NYSE: ... to the EMPHASIS-HF trial early on the recommendations of the trial,s ... analysis by the independent Data Safety Monitoring Committee (DSMC) of the ... early according to the protocol pre-defined stopping rules. , ...
... in the College of Engineering at Virginia Tech, has ... to support development of a carbon nanotube-enhanced composite for ... huge wind turbine blades. Powe awards provide seed ... member institutions. These awards are intended to enrich the ...
Cached Biology Technology:China Sky One Medical Receives GMP Re-Certification 2China Sky One Medical Receives GMP Re-Certification 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 2Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 3Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 4Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone) 5Powe Award supports development of nanocomposites to monitor wind turbine blade structure 2
(Date:5/19/2015)... -- Technology is rapidly advancing, outpacing enterprises, ability to secure ... and their management are soon to be rendered obsolete ... as those developed by the FIDO Alliance™. With the ... BYOD, COPE, IoT, and mobile payments, the interconnected online ... In response to the call for seamless, secure, ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Biological and Environmental Nanotechnology (CBEN) have developed a ... human cell that is programmed to light up ... of particular proteases is a common hallmark of ... the September issue of the journal Biochemical and ...
... The most detailed analysis to date of how humans differ ... that natural selection has shaped the recent evolution of our ... Celera Diagnostics. , In a study published in the ... 11,624 genes, comparing how genes vary not only among 39 ...
... a 'living gel' that could be applied to the ... , The researchers genetically modified bacteria that are normally ... protein that stops the HIV virus from infecting cells. ... the internal body surfaces where HIV transmission can occur ...
Cached Biology News:'Smart' nanoprobes light up disease 2Cornell finds natural selection in humans 2Cornell finds natural selection in humans 3Living anti-HIV gel shows early promise 2